BioNTech SE (BNTX) Share-based Compensation (2019 - 2025)
BioNTech SE (BNTX) posted Share-based Compensation of $28.1 million for Q4 2025, down 13.99% sequentially from $32.6 million in Q3 2025, and up 11.71% YoY from $25.1 million in Q4 2024.
BioNTech SE (BNTX) Share-based Compensation (2019 - 2025) Analysis & Trends
BioNTech SE has reported Share-based Compensation for 7 years, with the latest figure at $28.1 million in Q4 2025.
- Quarterly Share-based Compensation rose 11.71% year-over-year to $28.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $120.3 million (up 9.83% YoY) and the FY2025 annual result came in at $120.0 million, up 11.28% from the prior year.
- Share-based Compensation slipped to $28.1 million in Q4 2025 per BNTX's latest filing, from $32.6 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $73.6 million in Q3 2021 and troughed at $20.87 in Q1 2021.
- A 5-year average of $26.1 million and a median of $22.9 million in 2022 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 269441191.15% in 2021, down 100.0% in 2021.
- Over 5 years, Share-based Compensation stood at $23.5 million in 2021, then slipped by 3.42% to $22.6 million in 2022, then slumped by 32.54% to $15.3 million in 2023, then jumped by 64.36% to $25.1 million in 2024, then grew by 11.71% to $28.1 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $28.1 million, $32.6 million, and $36.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 28.05 Mn |
| Dec 31, 2025 | 28.05 Mn |
| Sep 30, 2025 | 32.62 Mn |
| Sep 30, 2025 | 32.62 Mn |
| Jun 30, 2025 | 36.34 Mn |
| Jun 30, 2025 | 36.34 Mn |
| Mar 31, 2025 | 23.25 Mn |
| Mar 31, 2025 | 23.25 Mn |
| Dec 31, 2024 | 25.11 Mn |
| Dec 31, 2024 | 25.11 Mn |
| Sep 30, 2024 | 44.92 Mn |
| Sep 30, 2024 | 44.92 Mn |
| Jun 30, 2024 | 21.75 Mn |
| Jun 30, 2024 | 21.75 Mn |
| Mar 31, 2024 | 17.71 Mn |
| Mar 31, 2024 | 17.71 Mn |
| Dec 31, 2023 | 15.28 Mn |
| Dec 31, 2023 | 15.28 Mn |
| Sep 30, 2023 | 16.87 Mn |
| Sep 30, 2023 | 16.87 Mn |